scholarly journals The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (40) ◽  
pp. 67851-67860 ◽  
Author(s):  
San-Gang Wu ◽  
Wen-Weng Zhang ◽  
Jia-Yuan Sun ◽  
Feng-Yan Li ◽  
Huan-Xin Lin ◽  
...  
2003 ◽  
Vol 29 (1) ◽  
pp. 17-19 ◽  
Author(s):  
A.R Carmichael ◽  
E.D.C Anderson ◽  
U Chetty ◽  
J.M Dixon

2018 ◽  
Vol Volume 10 ◽  
pp. 5329-5338 ◽  
Author(s):  
Weikai Xiao ◽  
Shaoquan Zheng ◽  
Anli Yang ◽  
Xingcai Zhang ◽  
Yutian Zou ◽  
...  

2018 ◽  
Vol 18 (1) ◽  
pp. e97-e105 ◽  
Author(s):  
Wei Chen ◽  
Ying Huang ◽  
Gary D. Lewis ◽  
Sean S. Szeja ◽  
Sandra S. Hatch ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
D. J. P. van Uden ◽  
M. C. van Maaren ◽  
L. J. A. Strobbe ◽  
P. Bult ◽  
J. J. van der Hoeven ◽  
...  

Abstract Background Distant metastatic disease is frequently observed in inflammatory breast cancer (IBC), with a poor prognosis as a consequence. The aim of this study was to analyze the association of hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) based breast cancer subtypes in stage IV inflammatory breast cancer (IBC) with preferential site of distant metastases and overall survival (OS). Methods For patients with stage IV IBC, diagnosed in the Netherlands between 2005 and 2016, tumors were classified into four breast cancer subtypes: HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2−. Patient, tumor, and treatment characteristics and sites of metastases were compared. OS of the subtypes was compared using Kaplan-Meier curves and the log-rank test. Association between subtype and OS was assessed in multivariable models using logistic regression. Results In total, 744 eligible patients were included: 340 (45.7%) tumors were HR+/HER2−, 148 (19.9%) HR−/HER2+, 131 (17.6%) HR+/HER2+, and 125 (16.8%) HR−/HER2−. Bone was the most common metastatic site in all subtypes. A significant predominance of bone metastases was found in HR+/HER2− IBC (71.5%), and liver and lung metastases in the HR−/HER2+ (41.2%) and HR−/HER2− (40.8%) subtypes, respectively. In multivariable analysis, the HR−/HER2− subtype was associated with significantly worse OS as compared to the other subtypes. Conclusion Breast cancer subtypes in stage IV IBC are associated with distinct patterns of metastatic spread and display notable differences in OS. The use of breast cancer subtypes can guide a more patient-tailored staging directed to metastatic site and extend of disease.


Breast Care ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. 411-417 ◽  
Author(s):  
Thomas Kolben ◽  
Theresa M. Kolben ◽  
Isabelle Himsl ◽  
Tom Degenhardt ◽  
Jutta Engel ◽  
...  

Background: This study aimed to identify the association of local surgery of the primary tumor in metastatic breast cancer (MBC) patients with overall survival (OS) and prognostic factors. Patients and Methods: Patients with primary MBC (1990-2006) were included in our retrospective analysis (n = 236). 83.1% had surgery for the primary tumor. OS was evaluated using Kaplan-Meier estimates. Predictive factors for OS were determined. Results: Median follow-up was 123 months for all patients still alive at the time of analysis. In univariate analysis, patients with surgery of the primary tumor had significantly prolonged OS (28.9 vs. 23.9 months). Within the surgery group, patients with MBC limited to 1 organ system had a better outcome (39.3 vs. 24.9 months), as did asymptomatic patients. Independent risk factors for shorter OS were hormone receptor negativity, symptoms, and involvement of ≥ 1 organ system. Conclusion: Patient selection for local therapy was confounded by a more favorable profile and a lesser tumor burden before surgery, which might implicate a bias. Nevertheless, our univariate results indicate that local surgery of the primary tumor in MBC patients could be considered as part of the therapeutic regimen in selected patients. However, larger patient numbers are needed to prove these findings in the multivariate model.


2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 22181-22181 ◽  
Author(s):  
A. A. Onitilo ◽  
J. Engel ◽  
R. T. Greenlee ◽  
B. Mukesh

Sign in / Sign up

Export Citation Format

Share Document